JP5214590B2 - 抗ウイルス薬としてのジケト−ピペラジンおよびピペリジン誘導体 - Google Patents

抗ウイルス薬としてのジケト−ピペラジンおよびピペリジン誘導体 Download PDF

Info

Publication number
JP5214590B2
JP5214590B2 JP2009507893A JP2009507893A JP5214590B2 JP 5214590 B2 JP5214590 B2 JP 5214590B2 JP 2009507893 A JP2009507893 A JP 2009507893A JP 2009507893 A JP2009507893 A JP 2009507893A JP 5214590 B2 JP5214590 B2 JP 5214590B2
Authority
JP
Japan
Prior art keywords
mixture
pyrrolo
phenyl
pyridin
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009507893A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009535352A5 (enExample
JP2009535352A (ja
Inventor
タオ・ワン
ジョン・エフ・カドー
チャン・チョンシン
ジウェイ・イン
ニコラス・エイ・ミーンウェル
アリシア・レゲイロ−レン
ジェイコブ・スウィドースキ
ハン・イン
デイビッド・ジェイ・カリーニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2009535352A publication Critical patent/JP2009535352A/ja
Publication of JP2009535352A5 publication Critical patent/JP2009535352A5/ja
Application granted granted Critical
Publication of JP5214590B2 publication Critical patent/JP5214590B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009507893A 2006-04-25 2007-04-16 抗ウイルス薬としてのジケト−ピペラジンおよびピペリジン誘導体 Active JP5214590B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US79470006P 2006-04-25 2006-04-25
US79470306P 2006-04-25 2006-04-25
US60/794,700 2006-04-25
US60/794,703 2006-04-25
US11/733,283 2007-04-10
US11/733,283 US7807671B2 (en) 2006-04-25 2007-04-10 Diketo-piperazine and piperidine derivatives as antiviral agents
PCT/US2007/066700 WO2007127635A2 (en) 2006-04-25 2007-04-16 Diketo-piperazine and piperidine derivatives as antiviral agents

Publications (3)

Publication Number Publication Date
JP2009535352A JP2009535352A (ja) 2009-10-01
JP2009535352A5 JP2009535352A5 (enExample) 2010-06-03
JP5214590B2 true JP5214590B2 (ja) 2013-06-19

Family

ID=38335673

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009507893A Active JP5214590B2 (ja) 2006-04-25 2007-04-16 抗ウイルス薬としてのジケト−ピペラジンおよびピペリジン誘導体

Country Status (17)

Country Link
US (2) US7807671B2 (enExample)
EP (1) EP2010525B1 (enExample)
JP (1) JP5214590B2 (enExample)
KR (1) KR101450349B1 (enExample)
AR (1) AR060658A1 (enExample)
AU (1) AU2007242989B2 (enExample)
BR (1) BRPI0710919A2 (enExample)
CA (1) CA2650382C (enExample)
EA (1) EA014957B1 (enExample)
ES (1) ES2432758T3 (enExample)
IL (1) IL194540A (enExample)
MX (1) MX2008013265A (enExample)
NO (1) NO341412B1 (enExample)
NZ (1) NZ571995A (enExample)
PE (1) PE20080318A1 (enExample)
TW (1) TWI394754B (enExample)
WO (1) WO2007127635A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
CA2687931C (en) * 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
JP5341084B2 (ja) * 2007-08-03 2013-11-13 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
WO2009158394A1 (en) * 2008-06-25 2009-12-30 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
CN102076686B (zh) 2008-06-25 2013-03-06 百时美施贵宝公司 作为hiv附着抑制剂的二酮哌啶衍生物
WO2010013849A1 (ja) * 2008-08-01 2010-02-04 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
ES2383149T3 (es) * 2008-09-04 2012-06-18 Bristol-Myers Squibb Company Composicion farmacéutica estable para la administración optimizada de un inhibidor de la unión del VIH
CN103724328B (zh) 2008-12-19 2015-10-14 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
WO2010126811A1 (en) * 2009-04-27 2010-11-04 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
PL2513093T3 (pl) 2009-12-17 2015-03-31 Centrexion Therapeutics Corp Nowi antagoniści receptora CCR2 i ich zastosowanie
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
JP5636094B2 (ja) 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体アンタゴニスト
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
JP5613461B2 (ja) * 2010-06-02 2014-10-22 日本農薬株式会社 ピリミジン誘導体及び該誘導体を含有する農園芸用殺虫剤並びにその使用方法
US20130096305A1 (en) * 2010-06-17 2013-04-18 Bristol-Myers Squibb Company Deuterated hiv attachment inhibitors
US8450361B2 (en) 2010-08-06 2013-05-28 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
ES2585396T3 (es) 2010-12-02 2016-10-05 VIIV Healthcare UK (No.5) Limited Alquilamidas como inhibidores de la unión del VIH
EP2696937B1 (en) * 2011-04-12 2017-05-17 VIIV Healthcare UK (No.5) Limited Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
US8859550B2 (en) 2011-09-12 2014-10-14 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
ES2616492T3 (es) * 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de piperidina amida como inhibidores de la fijación del VIH
JP6318156B2 (ja) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
ES2695350T3 (es) 2012-12-11 2019-01-03 Takeda Pharmaceuticals Co Compuesto heterocíclico
CN112521369A (zh) 2013-03-13 2021-03-19 福马治疗股份有限公司 用于抑制fasn的化合物及组合物
CN105283455B (zh) * 2013-03-27 2017-06-16 百时美施贵宝公司 作为hiv吸附抑制剂的2‑酮基酰胺衍生物
EP2978762A1 (en) * 2013-03-27 2016-02-03 Bristol-Myers Squibb Company Piperazine and homopiperazine derivatives as hiv attachment inhibitors
PL3024832T3 (pl) 2013-07-22 2018-10-31 Idorsia Pharmaceuticals Ltd Pochodne 1-(piperazyn-1-ylo)-2-([1,2,4]triazol-1-ilo)-etanonu
WO2015063709A1 (en) * 2013-10-31 2015-05-07 Ranbaxy Laboratories Limited Process for the preparation of 1-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazine
WO2015190613A1 (en) * 2014-06-09 2015-12-17 Takeda Pharmaceutical Company Limited Radiolabeled compounds
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
PL3245203T3 (pl) 2015-01-15 2019-05-31 Idorsia Pharmaceuticals Ltd Pochodne hydroksyalkilopiperazyny jako modulatory receptora cxcr3
AU2016287584B2 (en) 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
KR102014335B1 (ko) * 2017-12-01 2019-08-26 한국과학기술연구원 5-ht7 수용체의 조절제로 작용하는 아릴피라졸릴피페라진 또는 아릴피라졸릴다이아제페인의 유도체 및 이를 포함하는 중추신경계 질환 치료 또는 예방용 약학 조성물
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
MA54076A (fr) 2018-11-02 2022-02-09 Merck Sharp & Dohme 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
CN111004213B (zh) * 2019-12-26 2021-07-20 北京欣奕华科技有限公司 一种有机电致发光化合物及其应用
TW202321229A (zh) * 2021-08-18 2023-06-01 美商富曼西公司 殺真菌的取代的雜環化合物
US20240208980A1 (en) * 2022-12-19 2024-06-27 Navinta, Llc Fostemsavir Intermediates and Process for the Preparation Thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB944443A (enExample) 1959-09-25 1900-01-01
GB8615562D0 (en) 1986-06-25 1986-07-30 Maggioni Farma Aminoalcohols
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
US5023265A (en) 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
IL99843A0 (en) 1990-11-01 1992-08-18 Merck & Co Inc Synergistic combination of hiv reverse transcriptase inhibitors
US5811432A (en) 1990-11-09 1998-09-22 Pfizer Inc Azaoxindole derivatives
US5192770A (en) 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
DK0594702T3 (da) 1991-07-03 1997-07-21 Upjohn Co Substituerede indoler som midler mod AIDS
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
US5124327A (en) 1991-09-06 1992-06-23 Merck & Co., Inc. HIV reverse transcriptase
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IT1265057B1 (it) 1993-08-05 1996-10-28 Dompe Spa Tropil 7-azaindolil-3-carbossiamidi
US5424329A (en) 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
TW429256B (en) 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
CA2264231A1 (en) 1996-08-29 1998-03-05 Takeda Chemical Industries, Ltd. Cyclic ether compounds as sodium channel modulators
DE19636150A1 (de) 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
WO1998028292A1 (en) 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
AU1454599A (en) 1997-11-10 1999-05-31 Dana-Farber Cancer Institute Compounds inhibiting cd4-gp120 interaction and uses thereof
RU2217421C2 (ru) 1998-03-26 2003-11-27 Шионоги & Ко., Лтд. Производные индола, обладающие антивирусной активностью
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
HUP0101475A3 (en) 1998-06-19 2003-01-28 Lundbeck & Co As H 4,5,6 and 7-indole and indoline derivatives, their preparation and use
EP1091738B1 (en) 1998-06-30 2006-12-06 Eli Lilly And Company BICYCLIC sPLA 2 INHIBITORS
EP1107758A2 (en) 1998-08-28 2001-06-20 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
CZ20014126A3 (cs) 1999-05-21 2002-03-13 Scios Inc. Indolové deriváty jako inhibitory p38 kinasy
US6469006B1 (en) 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
TWI269654B (en) 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20020061892A1 (en) 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
DE60113543T2 (de) 2000-07-10 2006-07-13 Bristol-Myers Squibb Co. Zusammensetzung und antivirale wirkung von substituierten indol-oxo-aceto-piperidin-derivaten
US6573262B2 (en) 2000-07-10 2003-06-03 Bristol-Myers Sqibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
KR20030079979A (ko) 2001-02-02 2003-10-10 브리스톨-마이어스스퀴브컴파니 치환된 아자인돌옥소아세틱 피페라진 유도체의 조성물 및항바이러스 활성
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US6667378B2 (en) 2001-06-22 2003-12-23 L'oreal, S.A. Reshapable hair styling composition comprising heterogeneous (meth)acrylic copolymer particles
BR0214020A (pt) 2001-11-09 2004-10-13 Scios Inc Método para tratar fibrose cìstica
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
WO2003082881A2 (en) 2002-03-28 2003-10-09 Procyon Biopharma Inc. Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
US7037913B2 (en) 2002-05-01 2006-05-02 Bristol-Myers Squibb Company Bicyclo 4.4.0 antiviral derivatives
US20040063744A1 (en) 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US7348337B2 (en) 2002-05-28 2008-03-25 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US20040106104A1 (en) 2002-06-11 2004-06-03 Pin-Fang Lin Viral envelope mediated fusion assay
US6900206B2 (en) 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
US20040063746A1 (en) 2002-07-25 2004-04-01 Alicia Regueiro-Ren Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
OA13235A (en) 2003-08-14 2006-12-13 Pfizer Piperazine derivatives for the treatment of HIV infections.
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7776863B2 (en) 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
US20050215543A1 (en) 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
US20050215544A1 (en) 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
US7449476B2 (en) 2004-05-26 2008-11-11 Bristol-Myers Squibb Company Tetrahydrocarboline antiviral agents
US7087610B2 (en) 2004-06-03 2006-08-08 Bristol-Myers Squibb Company Benzothiazole antiviral agents
WO2005121094A1 (en) 2004-06-09 2005-12-22 Pfizer Limited Piperazine and piperidine derivatives as anti-hiv-agents
US20060100209A1 (en) 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7183284B2 (en) 2004-12-29 2007-02-27 Bristol-Myers Squibb Company Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
US7396830B2 (en) 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7501419B2 (en) 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
US7504399B2 (en) * 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents

Also Published As

Publication number Publication date
US7807671B2 (en) 2010-10-05
KR20090005393A (ko) 2009-01-13
WO2007127635A2 (en) 2007-11-08
AR060658A1 (es) 2008-07-02
IL194540A0 (en) 2009-08-03
TW200811174A (en) 2008-03-01
US20070249579A1 (en) 2007-10-25
BRPI0710919A2 (pt) 2012-06-26
CA2650382C (en) 2014-05-27
AU2007242989A1 (en) 2007-11-08
NZ571995A (en) 2011-11-25
CA2650382A1 (en) 2007-11-08
PE20080318A1 (es) 2008-04-10
EP2010525A2 (en) 2009-01-07
MX2008013265A (es) 2008-10-27
NO341412B1 (no) 2017-10-30
AU2007242989B2 (en) 2012-06-28
NO20084257L (no) 2008-11-19
IL194540A (en) 2015-03-31
TWI394754B (zh) 2013-05-01
EA200802203A1 (ru) 2009-04-28
EP2010525B1 (en) 2013-08-28
KR101450349B1 (ko) 2014-10-14
ES2432758T3 (es) 2013-12-05
US20080139572A1 (en) 2008-06-12
WO2007127635A3 (en) 2008-03-13
EA014957B1 (ru) 2011-04-29
JP2009535352A (ja) 2009-10-01
US7807676B2 (en) 2010-10-05

Similar Documents

Publication Publication Date Title
JP5214590B2 (ja) 抗ウイルス薬としてのジケト−ピペラジンおよびピペリジン誘導体
US7902204B2 (en) Diazaindole-dicarbonyl-piperazinyl antiviral agents
AU2003301958B2 (en) Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
AU2015291478B2 (en) Novel substituted pyrimidine compounds
JP5433691B2 (ja) Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体
CN119403551A (zh) Tea结构域家族成员的小分子抑制剂
JP2016515580A (ja) Ｈｉｖ結合阻害剤としての２−ケトアミド誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120918

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130227

R150 Certificate of patent or registration of utility model

Ref document number: 5214590

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160308

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250